Cardio, you are of course right, the drug didn't show stat significance in the primary prevention arm, but barely, and almost certainly would have with more patients and an extra year. The curves on the graphs from primary, given an extra year and a half, are nearly identical to secondary prevention and lead at least Deepak Bhatt to assume the same benefits would accrue. In fact, every graph bends towards geometric growing benefits as a function of time over all cohorts. And that 10-4-2 AdCom nod in favor of primary prevention seemed to be helped by FDA prodding.
News 
Market Data 
Discover 
AI
